Bupropion Treatment of Serotonin Reuptake Antidepressant-Associated Sexual Dysfunction

Labbate, Lawrence A.; Grimes, Jamie; Hines, Alan; Pollack, Mark H.

doi:10.3109/10401239709147804

Cited by 56 publications

(36 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The evidence for bupropion augmentation is the most compelling. 31 Finally, there is firm evidence that remedial drug therapy with sildenafil, the selective and competitive inhibitor of phosphodiesterase type 5 (PDE-5), has proved effective in men for antidepressant-induced erectile dysfunction, 32 and more recently -although not licensed for this group -in women with SSRI-and SNRI-induced sexual adverse effects. 33 Its characteristics of peripheral site of action, high efficacy, good tolerability, relatively short duration of action and administration only if and when required make this agent in some ways the ideal antidote.…”

Section: Management Of Antidepressant-induced Sexual Dysfunctionmentioning

confidence: 99%

Antidepressant-induced sexual dysfunction

Outhoff

2009

South African Family Practice

View full text Add to dashboard Cite

Depression and sexual dysfunction are both common in the general population. When they co-exist they have the potential to impact negatively on each other in a bidirectional manner. Medication used to treat depression may cause additional problems with the sexual response cycle; although no drug is completely innocent, serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) are most frequently implicated in antidepressant-induced sexual dysfunction. Adherence to long-term treatment may be compromised, which may have serious consequences. Various psychological and pharmacological strategies, including the ad hoc use of sildenafil, may offer some respite.

show abstract

Section: Management Of Antidepressant-induced Sexual Dysfunctionmentioning

confidence: 99%

Antidepressant-induced sexual dysfunction

Outhoff

2009

South African Family Practice

View full text Add to dashboard Cite

show abstract

“…Buproprion is a dopamine and norepinephrine reuptake inhibitor that has been an effective antidote for the side effect of DE from SSRIs in some studies (Labbate et al, 1997;Ashton & Rosen, 1998;DeBattista et al, 2005). Many of the other drugs commonly used for DE have also been investigated as a treatment to counter the effects of SSRIs.…”

Section: Discussionmentioning

confidence: 99%

How is delayed ejaculation defined and treated in North America?

et al. 2015

View full text Add to dashboard Cite

SUMMARYDelayed ejaculation (DE) is an uncommon disorder that is difficult to treat because it is poorly understood. The aim was to evaluate the current opinion and clinical management of DE by practitioners in sexual medicine. Members of the Sexual Medicine Society of North America (SMSNA) were invited by email to participate in a web-based survey. The questionnaire consisted of eight questions pertaining to DE. Questions addressed patient volume, qualification of patient bother, ranking of etiologies, perceived success, treatments used, quantification of symptom resolution, and broad characterization of practitioner type. A total of 94 respondents completed the survey with 73% of those being urologists. Fifty-nine percent of the respondents saw ≤ 2 patients a month with DE and 89% of practitioners felt that DE was moderately or severely bothersome to the patients. Etiology was felt to be from medications and psychological factors primarily. Despite treatment modality, 'seldom' success was obtained for 49% of the time and 'never' for 11%. Carbergoline was the most common selected medication for DE. Academic and private urologists reported 'never' or 'seldom' success with sexual counseling compared to other practitioners, respectively (p = 0.008 and p = 0.001). Respondents who saw ≤ 2 patients per month often reported normalization of hypogonadism 'never' or 'seldom' corrected DE (p = 0.047). Delayed ejaculation is still a poorly understood disorder with inconsistent practice patterns seen among members of the SMSNA. A better understanding of this vexing disorder is needed with efforts placed on research and practitioner education.

show abstract

“…In male rats, it was shown that the increase in dopaminergic activity in medial preoptic area lead to an increased sexual activity (18), and inversely, increase in serotonergic activity in this area, decreased it (19). In some studies, SSRI induced sexual dysfunction improved after bupropion augmentation (20)(21)(22). In a study comprised of 8 patients suffering from SSRI induced sexual dysfunction, it was reported that 2 months after bupropion augmentation, sexual dysfunction significantly improved in 4 patients.…”

mentioning

confidence: 99%

“…In a study comprised of 8 patients suffering from SSRI induced sexual dysfunction, it was reported that 2 months after bupropion augmentation, sexual dysfunction significantly improved in 4 patients. In this study bupropion was considered as a treatment option in patients suffering from SSRI induced sexual dysfunction (21). In a similar study comprised of 47 patients with SSRI induced sexual dysfunction, 75 mg and 150 mg doses of bupropion were given and 2 weeks later sexual dysfunction was improved in 31 patients.…”

mentioning

confidence: 99%